- Accelera Recognised as Key Partner in the Development of a New Therapy
The development of fexinidazole for the treatment of Africantrypanosomiasis, commonly known as "sleeping sickness", by DNDi (Drugs forNeglected Diseases initiative), along with Accelera, a business unit ofNerviano Medical Sciences (NMS), is to be honoured as one of DNDi's SuccessStories of the Year. The award will be conferred today in New York, at theprestigious headquarters of the New York Academy of Sciences, during thefirst annual Stakeholders' Meeting of DNDi. Accelera is recognised as DNDi'skey partner in the non-clinical development of fexinidazole.
Advertisement
"We are proud to receive this recognition," comments Dr. Marco Brughera -Vice President of Accelera - "and happy to be able to contribute to improvingthe health of populations living in the poorest countries. We were delightedto be selected from among several international Contract ResearchOrganisations (CROs) to be DNDi's partner of choice for characterizing thepreclinical profile of fexinidazole"
Advertisement
"The preclinical work to support the profiling of fexinidazole started atAccelera more than one year ago," Dr Brughera points out "and included aseries of in vitro and preliminary activities followed by a full package oftolerability and safety studies as requested by Regulatory Authorities. Theresults obtained have allowed DNDi to proceed to the next stage offexinidazole's development, with a quick registration being a primary goal."
Accelera carries out preclinical development activities for moleculestargeting various different therapeutic classes, including collaborationsaimed at defining therapeutic solutions for other "neglected diseases," suchas malaria, visceral leishmaniasis, African trypanosomiasis, and Chagas'disease.
"Our pride in this recognition is twofold: on the one hand there is thesatisfaction of being an active collaborator within such internationalprojects, and on the other the knowledge that we have been able to make ourcontribution to a humanitarian initiative like that of DNDi," continuesGiampiero Duglio, Managing Director of NMS.
About Accelera (http://www.accelera.info)
Accelera, BU of Nerviano Medical Sciences, is a premium tier ContractResearch Organization (CRO), working and collaborating with pharmaceuticaland biotechnology companies around the world. Committed to offering thehighest levels of service throughout drug discovery and development, ourexpertise can make a difference, right from the start.
About Nerviano Medical Sciences - NMS (http://www.nervianoms.com)
NMS is a research based company dedicated to the discovery anddevelopment of breakthrough new chemical entities (NCEs) for the treatment ofcancer. NMS was incorporated in May 2004 as a spin-off from Pfizer and iswholly owned by the Rome-based Congregazione dei Figli dell'ImmacolataConcezione (CFIC).For further information please contact: Accelera (Nerviano Medical Sciences) Maria D'Acquino, mob +39-335-1863052 maria.d'[email protected]
SOURCE Nerviano Medical Sciences (NMS): Accelera
